公开(公告)号：WO2008063202A3

公开(公告)日：2008-05-29

申请号：PCT/US2007/002352

申请日：2007-01-30

Applicant: ARRAY BIOPHARMA INC. ,  BLAKE, James, F. ,  BOYD, Steven ,  DE MEESE, Jason ,  GAUDINO, John, J. ,  MARLOW, Allison, L. ,  SEO, Jeongbeob ,  THOMAS, Allen, A. ,  TIAN, Hongqi

Inventor： BLAKE, James, F. ,  BOYD, Steven ,  DE MEESE, Jason ,  GAUDINO, John, J. ,  MARLOW, Allison, L. ,  SEO, Jeongbeob ,  THOMAS, Allen, A. ,  TIAN, Hongqi

IPC: C07D495/04 ,  C07D519/00 ,  A61K31/4353 ,  A61P35/00

Abstract: Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：EP2681215B1

公开(公告)日：2015-04-22

申请号：EP12709429.0

申请日：2012-02-28

Applicant: Array Biopharma, Inc. ,  Genentech, Inc.

Inventor： BLAKE, James F. ,  CHEN, Huifen ,  CHICARELLI, Mark Joseph ,  DEMEESE, Jason ,  GARREY, Rustam ,  GAUDINO, John J. ,  KAUS, Robert J. ,  KOLAKOWSKI, Gabrielle R. ,  MARLOW, Allison L. ,  MOHR, Peter J. ,  REN, Li ,  SCHWARZ, Jacob ,  SIEDEM, Christopher S. ,  THOMAS, Allen A. ,  WALLACE, Eli ,  WENGLOWSKY, Steven Mark ,  BOYD, Steven

IPC: C07D471/04 ,  A61K31/519 ,  A61P35/00

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61K45/06 ,  C07D491/052

公开(公告)号：EP1989211A2

公开(公告)日：2008-11-12

申请号：EP07870652.0

申请日：2007-01-30

Applicant: Array Biopharma, Inc.

Inventor： BLAKE, James, F. ,  BOYD, Steven ,  DE MEESE, Jason ,  GAUDINO, John J. ,  MARLOW, Allison L. ,  SEO, Jeongbeob ,  THOMAS, Allen A. ,  TIAN, Hongqi

IPC: C07D495/04

CPC classification number: C07D495/04 ,  C07D519/00

Abstract: Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.